{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T18:29:41Z","timestamp":1791224981439,"version":"4.1.0"},"reference-count":142,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["cgfr.co.uk","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine &amp; Growth Factor Reviews"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1016\/j.cytogfr.2014.12.006","type":"journal-article","created":{"date-parts":[[2014,12,30]],"date-time":"2014-12-30T17:32:08Z","timestamp":1419960728000},"page":"121-131","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":62,"title":["Twenty-five years of type I interferon-based treatment: A critical analysis of its therapeutic use"],"prefix":"10.1016","volume":"26","author":[{"given":"Guido","family":"Antonelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Scagnolari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Moschella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Proietti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cytogfr.2014.12.006_bib0715","series-title":"Interferon: the science and selling of a miracle drug","author":"Pieters","year":"2005"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib0720","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1098\/rspb.1957.0048","article-title":"Virus interference. I. The interferon","volume":"147","author":"Isaacs","year":"1957","journal-title":"Proc R Soc Lond B Biol Sci"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib0725","doi-asserted-by":"crossref","first-page":"799","DOI":"10.3181\/00379727-108-27072","article-title":"Production of interferon by suspensions of human leucocytes","volume":"108","author":"Gresser","year":"1961","journal-title":"Proc Soc Exp Biol Med"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib0730","first-page":"265","article-title":"Production of interferon by human leukocytes in vitro","volume":"44","author":"Strander","year":"1966","journal-title":"Ann Med Exp Biol Fenn"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib0735","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/978-3-642-81332-0_7","article-title":"Adjuvant interferon treatment of human osteosarcoma","volume":"68","author":"Strander","year":"1978","journal-title":"Recent Results Cancer Res"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib0740","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1073\/pnas.63.1.51","article-title":"Increased survival in mice inoculated with tumor cells and treated with interferon preparations","volume":"63","author":"Gresser","year":"1969","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib0745","first-page":"755","article-title":"The action of interferons on virus-associated human neoplasms","volume":"8","author":"Strander","year":"1989","journal-title":"Cancer Surv"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib0750","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1056\/NEJM197609022951009","article-title":"Editorial: interferon and hepatitis B virus","volume":"295","author":"Ho","year":"1976","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib0755","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1056\/NEJM197609022951001","article-title":"Effect of human leukocyte interferon on hepatitis B virus infection in patients with chronic active hepatitis","volume":"295","author":"Greenberg","year":"1976","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib0760","doi-asserted-by":"crossref","first-page":"464","DOI":"10.2183\/pjab.55.464","article-title":"Construction and identification of a bacterial plasmid containing the human fibroblast interferon gene sequence","volume":"55B","author":"Taniguchi","year":"1979","journal-title":"Proc Jpn Acad"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib0765","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/284316a0","article-title":"Synthesis in E. coli of a polypeptide with human leukocyte interferon activity","volume":"284","author":"Nagata","year":"1980","journal-title":"Nature"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib0770","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1038\/298859a0","article-title":"Structure of the human immune interferon gene","volume":"298","author":"Gray","year":"1982","journal-title":"Nature"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib0775","doi-asserted-by":"crossref","first-page":"9750","DOI":"10.1016\/S0021-9258(19)68827-7","article-title":"Purification and characterization of recombinant human leukocyte interferon (IFLrA) with monoclonal antibodies","volume":"256","author":"Staehelin","year":"1981","journal-title":"J Biol Chem"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib0780","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1126\/science.6186023","article-title":"Secretion of human interferons by yeast","volume":"219","author":"Hitzeman","year":"1983","journal-title":"Science"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib0785","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/285542a0","article-title":"Isolation and structure of a human fibroblast interferon gene","volume":"285","author":"Derynck","year":"1980","journal-title":"Nature"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib0790","doi-asserted-by":"crossref","first-page":"4057","DOI":"10.1093\/nar\/8.18.4057","article-title":"Synthesis of human fibroblast interferon by E. coli","volume":"8","author":"Goeddel","year":"1980","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib0795","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa040431","article-title":"Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B","volume":"351","author":"Marcellin","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib0800","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1517\/14712598.2013.764409","article-title":"Antiviral activity of the interferon alpha family: biological and pharmacological aspects of the treatment of chronic hepatitis C","volume":"13","author":"Scagnolari","year":"2013","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib0805","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1089\/jir.2010.0125","article-title":"Pandemic 2009 H1N1 influenza virus is resistant to the antiviral activity of several interferon alpha subtypes","volume":"31","author":"Scagnolari","year":"2011","journal-title":"J Interferon Cytokine Res"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib0810","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1089\/vim.2010.0073","article-title":"In vitro sensitivity of human metapneumovirus to type I interferons","volume":"24","author":"Scagnolari","year":"2011","journal-title":"Viral Immunol"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib0815","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1111\/bph.12010","article-title":"IFN-alpha subtypes: distinct biological activities in anti-viral therapy","volume":"168","author":"Gibbert","year":"2013","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib0820","doi-asserted-by":"crossref","first-page":"e184","DOI":"10.1038\/bcj.2014.3","article-title":"Hairy cell leukemia: short review, today's recommendations and outlook","volume":"4","author":"Maevis","year":"2014","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib0825","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJM199005173222005","article-title":"Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy","volume":"322","author":"Mandelli","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib0830","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004629.pub2","article-title":"Interferon-alpha for maintenance of follicular lymphoma","author":"Baldo","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib0835","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/ajh.23615","article-title":"Mantle cell lymphoma: 2013 update on diagnosis, risk-stratification, and clinical management","volume":"88","author":"Vose","year":"2013","journal-title":"Am J Hematol"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib0840","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.jaad.2012.04.018","article-title":"Treatments for classic Kaposi sarcoma: a systematic review of the literature","volume":"68","author":"Regnier-Rosencher","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib0845","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.ctrv.2014.06.005","article-title":"Systematic review of combination therapies for mycosis fungoides","volume":"40","author":"Humme","year":"2014","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib0850","doi-asserted-by":"crossref","first-page":"4943","DOI":"10.1158\/0008-5472.CAN-05-3396","article-title":"Immunization of stage IV melanoma patients with Melan-A\/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte\/dendritic cell precursors","volume":"66","author":"Di Pucchio","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib0855","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1200\/JCO.2006.10.1709","article-title":"Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous melanoma","volume":"25","author":"Mitchell","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib0860","first-page":"10","article-title":"Regulation of neoplastic angiogenesis","author":"Fidler","year":"2001","journal-title":"J Natl Cancer Inst Monogr"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib0865","doi-asserted-by":"crossref","first-page":"204","DOI":"10.3109\/08916930903510880","article-title":"Recent advances on the immunomodulatory effects of IFN-alpha: implications for cancer immunotherapy and autoimmunity","volume":"43","author":"Rizza","year":"2010","journal-title":"Autoimmunity"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib0870","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1749-6632.1989.tb16476.x","article-title":"Interferons and the differentiation of friend cells","volume":"567","author":"Rossi","year":"1989","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib0875","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1089\/jir.2012.0110","article-title":"Interferons as inducers of apoptosis in malignant cells","volume":"33","author":"Kotredes","year":"2013","journal-title":"J Interferon Cytokine Res"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib0880","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/nrd2422","article-title":"Interferons at age 50: past, current and future impact on biomedicine","volume":"6","author":"Borden","year":"2007","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib0885","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1056\/NEJM198612183152503","article-title":"Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report","volume":"315","author":"Hoofnagle","year":"1986","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib0890","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.antiviral.2013.09.020","article-title":"Host-targeting agents in the treatment of hepatitis C: a beginning and an end","volume":"100","author":"Baugh","year":"2013","journal-title":"Antiviral Res"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib0895","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJMoa1209026","article-title":"Treatment of HCV infection by targeting microRNA","volume":"368","author":"Janssen","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib0900","doi-asserted-by":"crossref","first-page":"e1003298","DOI":"10.1371\/journal.ppat.1003298","article-title":"Systems analysis of a RIG-I agonist inducing broad spectrum inhibition of virus infectivity","volume":"9","author":"Goulet","year":"2013","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib0905","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0140-6736(03)13973-6","article-title":"Treatment of SARS with human interferons","volume":"362","author":"Cinatl","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib0910","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1177\/135965350400900618","article-title":"Increased sensitivity of SARS-coronavirus to a combination of human type I and type II interferons","volume":"9","author":"Scagnolari","year":"2004","journal-title":"Antivir Ther"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib0915","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1128\/JVI.01619-09","article-title":"Pandemic H1N1 2009 influenza A virus induces weak cytokine responses in human macrophages and dendritic cells and is highly sensitive to the antiviral actions of interferons","volume":"84","author":"Osterlund","year":"2010","journal-title":"J Virol"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib0920","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1038\/nm.2879","article-title":"Lethal H5N1 influenza viruses are not resistant to interferon action in human, simian, porcine or chicken cells","volume":"18","author":"Ngunjiri","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib0925","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1038\/nm.3362","article-title":"Treatment with interferon-alpha2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques","volume":"19","author":"Falzarano","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib0930","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(14)70920-X","article-title":"Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study","author":"Omrani","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib0935","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/nri3581","article-title":"Regulation of type I interferon responses","volume":"14","author":"Ivashkiv","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib0940","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/icb.2012.9","article-title":"The interferons and their receptors \u2013 distribution and regulation","volume":"90","author":"de Weerd","year":"2012","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib0945","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1042\/BJ20060272","article-title":"TYK2 activity promotes ligand-induced IFNAR1 proteolysis","volume":"397","author":"Marijanovic","year":"2006","journal-title":"Biochem J"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib0950","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0021-9258(17)42492-6","article-title":"Transcriptional induction by interferon. New protein(s) determine the extent and length of the induction","volume":"261","author":"Larner","year":"1986","journal-title":"J Biol Chem"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib0955","doi-asserted-by":"crossref","first-page":"4841","DOI":"10.1128\/MCB.00224-09","article-title":"Alpha interferon induces long-lasting refractoriness of JAK\u2013STAT signaling in the mouse liver through induction of USP18\/UBP43","volume":"29","author":"Sarasin-Filipowicz","year":"2009","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib0960","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/ni1287","article-title":"Suppressor of cytokine signaling 1 regulates the immune response to infection by a unique inhibition of type I interferon activity","volume":"7","author":"Fenner","year":"2006","journal-title":"Nat Immunol"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib0965","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1038\/sj.emboj.7601149","article-title":"UBP43 is a novel regulator of interferon signaling independent of its ISG15 isopeptidase activity","volume":"25","author":"Malakhova","year":"2006","journal-title":"EMBO J"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib0970","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1172\/JCI70408","article-title":"Pegylated IFN-alpha regulates hepatic gene expression through transient Jak\/STAT activation","volume":"124","author":"Dill","year":"2014","journal-title":"J Clin Invest"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib0975","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1053\/j.gastro.2005.01.059","article-title":"Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection","volume":"128","author":"Chen","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib0980","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1053\/j.gastro.2006.08.043","article-title":"Silencing of USP18 potentiates the antiviral activity of interferon against hepatitis C virus infection","volume":"131","author":"Randall","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib0985","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1158\/1535-7163.MCT-12-0248","article-title":"Evidence for the ubiquitin protease UBP43 as an antineoplastic target","volume":"11","author":"Guo","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib0990","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/ni.2576","article-title":"The microRNA miR-155 controls CD8(+) T cell responses by regulating interferon signaling","volume":"14","author":"Gracias","year":"2013","journal-title":"Nat Immunol"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib0995","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.virol.2014.06.024","article-title":"MiR-221 accentuates IFNs anti-HCV effect by downregulating SOCS1 and SOCS3","volume":"462\u2013463","author":"Xu","year":"2014","journal-title":"Virology"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib1000","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1056\/NEJMoa0901282","article-title":"MicroRNA expression, survival, and response to interferon in liver cancer","volume":"361","author":"Ji","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib1005","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s11894-012-0309-x","article-title":"Treatment of hepatitis C: how will we use viral kinetics, response-guided therapy?","volume":"15","author":"Pawlotsky","year":"2013","journal-title":"Curr Gastroenterol Rep"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib1010","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1172\/JCI118025","article-title":"Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region","volume":"96","author":"Enomoto","year":"1995","journal-title":"J Clin Invest"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib1015","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1056\/NEJM199601113340203","article-title":"Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection","volume":"334","author":"Enomoto","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib1020","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1002\/hep.510250343","article-title":"Analysis of genotypes and amino acid residues 2209 to 2248 of the NS5A region of hepatitis C virus in relation to the response to interferon-beta therapy","volume":"25","author":"Kurosaki","year":"1997","journal-title":"Hepatology"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib1025","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/(SICI)1096-9071(199712)53:4<361::AID-JMV8>3.0.CO;2-5","article-title":"Mutations in the nonstructural protein 5A gene and response to interferon therapy in young patients with chronic hepatitis C virus 1b infection","volume":"53","author":"Komatsu","year":"1997","journal-title":"J Med Virol"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib1030","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jcv.2004.08.004","article-title":"Hepatitis C virus-related resistance mechanisms to interferon alpha-based antiviral therapy","volume":"32","author":"Hofmann","year":"2005","journal-title":"J Clin Virol"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib1035","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1053\/jhep.2000.20527","article-title":"Mutations in the E2-PePHD and NS5A region of hepatitis C virus type 1 and the dynamics of hepatitis C viremia decline during interferon alfa treatment","volume":"32","author":"Berg","year":"2000","journal-title":"Hepatology"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib1040","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/j.1440-1746.2003.03319.x","article-title":"Does sequencing the PKRBD of hepatitis C virus NS5A predict therapeutic response to combination therapy in an Australian population","volume":"19","author":"Macquillan","year":"2004","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib1045","doi-asserted-by":"crossref","first-page":"6644","DOI":"10.1128\/JVI.02231-07","article-title":"Mutations in E2-PePHD, NS5A-PKRBD, NS5A-ISDR, and NS5A-V3 of hepatitis C virus genotype 1 and their relationships to pegylated interferon-ribavirin treatment responses","volume":"82","author":"Munoz de Rueda","year":"2008","journal-title":"J Virol"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib1050","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1053\/gast.2000.20230","article-title":"Two PKR inhibitor HCV proteins correlate with early but not sustained response to interferon","volume":"119","author":"Gerotto","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib1055","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1007\/s00535-009-0126-7","article-title":"Viral factors influencing the response to the combination therapy of peginterferon plus ribavirin in chronic hepatitis C","volume":"44","author":"Maekawa","year":"2009","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib1060","doi-asserted-by":"crossref","first-page":"3886","DOI":"10.1128\/JCM.02109-12","article-title":"NS5A sequence heterogeneity of hepatitis C virus genotype 4a predicts clinical outcome of pegylated-interferon-ribavirin therapy in Egyptian patients","volume":"50","author":"El-Shamy","year":"2012","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib1065","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1002\/hep.23426","article-title":"Cleavage of mitochondrial antiviral signaling protein in the liver of patients with chronic hepatitis C correlates with a reduced activation of the endogenous interferon system","volume":"51","author":"Bellecave","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib1070","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/hep.23690","article-title":"Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin","volume":"52","author":"Akuta","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib1075","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1002\/hep.25826","article-title":"Comprehensive analysis for viral elements and interleukin-28B polymorphisms in response to pegylated interferon plus ribavirin therapy in hepatitis C virus 1B infection","volume":"56","author":"Maekawa","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib1080","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nature08309","article-title":"Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance","volume":"461","author":"Ge","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib1085","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/nature08463","article-title":"Genetic variation in IL28B and spontaneous clearance of hepatitis C virus","volume":"461","author":"Thomas","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib1090","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/ng.447","article-title":"IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy","volume":"41","author":"Suppiah","year":"2009","journal-title":"Nat Genet"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib1095","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/ng.449","article-title":"Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C","volume":"41","author":"Tanaka","year":"2009","journal-title":"Nat Genet"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib1100","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1089\/107999099314171","article-title":"Correlation of interferon-induced expression of MxA mRNA in peripheral blood mononuclear cells with the response of patients with chronic active hepatitis C to IFN-alpha therapy","volume":"19","author":"Antonelli","year":"1999","journal-title":"J Interferon Cytokine Res"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib1105","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1053\/jhep.2003.50105","article-title":"Interferon alfa regulated gene expression in patients initiating interferon treatment for chronic hepatitis C","volume":"37","author":"Ji","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib1110","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/nri3463","article-title":"25 years of interferon-based treatment of chronic hepatitis C: an epoch coming to an end","volume":"13","author":"Heim","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib1115","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1089\/jir.2004.24.659","article-title":"MxA and PKR expression in chronic hepatitis C","volume":"24","author":"Giannelli","year":"2004","journal-title":"J Interferon Cytokine Res"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib1120","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1002\/hep.22571","article-title":"A fresh look at interferon-alpha signaling and treatment outcomes in chronic hepatitis C","volume":"48","author":"Bellecave","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib1125","doi-asserted-by":"crossref","first-page":"7034","DOI":"10.1073\/pnas.0707882105","article-title":"Interferon signaling and treatment outcome in chronic hepatitis C","volume":"105","author":"Sarasin-Filipowicz","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib1130","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/j.1365-2249.2006.03280.x","article-title":"Expression of biomarkers of interferon type I in patients suffering from chronic diseases","volume":"147","author":"Scagnolari","year":"2007","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib1135","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1053\/j.gastro.2012.05.044","article-title":"Interferon-gamma-stimulated genes, but not USP18, are expressed in livers of patients with acute hepatitis C","volume":"143","author":"Dill","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib1140","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jhep.2011.07.017","article-title":"Targeted impairment of innate antiviral responses in the liver of chronic hepatitis C patients","volume":"56","author":"Jouan","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib1145","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1053\/j.gastro.2012.10.044","article-title":"Innate immune tolerance and the role of kupffer cells in differential responses to interferon therapy among patients with HCV genotype 1 infection","volume":"144","author":"Lau","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib1150","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1002\/hep.26657","article-title":"Dynamic expression profiling of type I and type III interferon-stimulated hepatocytes reveals a stable hierarchy of gene expression","volume":"59","author":"Bolen","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib1155","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1002\/hep.26959","article-title":"Type I and type III interferon-induced immune response: it's a matter of kinetics and magnitude","volume":"59","author":"Olagnier","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib1160","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1038\/ni.2667","article-title":"Structural basis of a unique interferon-beta signaling axis mediated via the receptor IFNAR1","volume":"14","author":"de Weerd","year":"2013","journal-title":"Nat Immunol"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib1165","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/ng.2521","article-title":"A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus","volume":"45","author":"Prokunina-Olsson","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib1170","doi-asserted-by":"crossref","DOI":"10.1111\/1469-0691.12797","article-title":"Hepatitis C virus and interferon type III (interferon lambda 3\/interleukin 28B and interferon lambda 4): genetic basis of susceptibility to infection and response to antiviral treatment","author":"Riva","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib1175","doi-asserted-by":"crossref","first-page":"e84026","DOI":"10.1371\/journal.pone.0084026","article-title":"Interferon-lambda4 (IFNL4) transcript expression in human liver tissue samples","volume":"8","author":"Amanzada","year":"2013","journal-title":"PLOS ONE"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib1180","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1172\/JCI75938","article-title":"Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome","volume":"124","author":"Meissner","year":"2014","journal-title":"J Clin Invest"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib1185","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/hep.23985","article-title":"Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models","volume":"53","author":"Thomas","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib1190","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1093\/infdis\/jis025","article-title":"Ribavirin regulates hepatitis C virus replication through enhancing interferon-stimulated genes and interleukin 8","volume":"205","author":"Tokumoto","year":"2012","journal-title":"J Infect Dis"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib1195","first-page":"231","article-title":"Antitumor effects of interferon","volume":"516","author":"Gresser","year":"1978","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib1200","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1002\/ijc.2910300622","article-title":"Antitumor effects of interferon in mice injected with interferon-sensitive and interferon-resistant Friend leukemia cells. II. Role of host mechanisms","volume":"30","author":"Belardelli","year":"1982","journal-title":"Int J Cancer"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib1205","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1359-6101(01)00022-3","article-title":"Interferon-alpha in tumor immunity and immunotherapy","volume":"13","author":"Belardelli","year":"2002","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib1210","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1749-6632.2010.05464.x","article-title":"Combination strategies for enhancing the efficacy of immunotherapy in cancer patients","volume":"1194","author":"Moschella","year":"2010","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib1215","first-page":"327","article-title":"Enhanced expression in vivo of HLA-ABC antigens and beta 2-microglobulin on human lymphoid cells induced by human interferon-alpha in patients with lung cancer. Enhanced expression of class I major histocompatibility antigens prior to treatment","volume":"59","author":"Nissen","year":"1985","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib1220","doi-asserted-by":"crossref","first-page":"3643","DOI":"10.4049\/jimmunol.144.9.3643","article-title":"IFN-alpha and IFN-gamma can affect both monocytes and tumor cells to modulate monocyte-mediated cytotoxicity","volume":"144","author":"Webb","year":"1990","journal-title":"J Immunol"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib1225","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1084\/jem.147.5.1314","article-title":"Anti-viral activity induced by culturing lymphocytes with tumor-derived or virus-transformed cells. Enhancement of human natural killer cell activity by interferon and antagonistic inhibition of susceptibility of target cells to lysis","volume":"147","author":"Trinchieri","year":"1978","journal-title":"J Exp Med"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib1230","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1126\/science.272.5270.1947","article-title":"Induction of bystander T cell proliferation by viruses and type I interferon in vivo","volume":"272","author":"Tough","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib1235","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/jlb.64.3.358","article-title":"Interferon-alpha and granulocyte-macrophage colony-stimulating factor differentiate peripheral blood monocytes into potent antigen-presenting cells","volume":"64","author":"Paquette","year":"1998","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib1240","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1084\/jem.191.10.1777","article-title":"Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice","volume":"191","author":"Santini","year":"2000","journal-title":"J Exp Med"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib1245","first-page":"2022","article-title":"Gene expression profiling and functional activity of human dendritic cells induced with IFN-alpha-2b: implications for cancer immunotherapy","volume":"9","author":"Moschella","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib1250","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1084\/jem.178.5.1655","article-title":"Interferon alpha increases the frequency of interferon gamma-producing human CD4+ T cells","volume":"178","author":"Brinkmann","year":"1993","journal-title":"J Exp Med"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib1255","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S1074-7613(01)00126-1","article-title":"Type I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo","volume":"14","author":"Le Bon","year":"2001","journal-title":"Immunity"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib1260","doi-asserted-by":"crossref","first-page":"5969","DOI":"10.4049\/jimmunol.0900526","article-title":"APC activation by IFN-alpha decreases regulatory T cell and enhances Th cell functions","volume":"184","author":"Pace","year":"2010","journal-title":"J Immunol"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib1265","doi-asserted-by":"crossref","first-page":"5647","DOI":"10.1158\/0008-5472.CAN-12-3788","article-title":"Interferon-alpha suppresses cAMP to disarm human regulatory T cells","volume":"73","author":"Bacher","year":"2013","journal-title":"Cancer Res"},{"issue":"Suppl. 2","key":"10.1016\/j.cytogfr.2014.12.006_bib1270","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.vaccine.2005.01.121","article-title":"Type I IFN as a vaccine adjuvant for both systemic and mucosal vaccination against influenza virus","volume":"24","author":"Bracci","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib1275","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1038\/nm.3708","article-title":"Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy","volume":"20","author":"Sistigu","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib1280","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa053007","article-title":"Prognostic significance of autoimmunity during treatment of melanoma with interferon","volume":"354","author":"Gogas","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib1285","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/S0168-8278(97)80171-7","article-title":"Interleukin-1 receptor antagonist plasma concentration is specifically increased by alpha-2A-interferon treatment","volume":"27","author":"Naveau","year":"1997","journal-title":"J Hepatol"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib1290","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1089\/10799900252982025","article-title":"Induction of IL-1Ra in resistant and responsive hepatitis C patients following treatment with IFN-con1","volume":"22","author":"Cotler","year":"2002","journal-title":"J Interferon Cytokine Res"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib1295","doi-asserted-by":"crossref","first-page":"e105665","DOI":"10.1371\/journal.pone.0105665","article-title":"The dynamic relationship between innate immune biomarkers and interferon-based treatment effects and outcome in hepatitis C virus infection is altered by telaprevir","volume":"9","author":"Malone","year":"2014","journal-title":"PLOS ONE"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib1300","article-title":"Is hepatitis C virus eradication around the corner only 25 years after its discovery?","author":"Ippolito","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib1305","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1146\/annurev.immunol.18.1.767","article-title":"Immunobiology of dendritic cells","volume":"18","author":"Banchereau","year":"2000","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib1310","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.4049\/jimmunol.165.7.3571","article-title":"Distinct requirements for IFNs and STAT1 in NK cell function","volume":"165","author":"Lee","year":"2000","journal-title":"J Immunol"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib1315","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.immuni.2006.08.010","article-title":"Type I interferon in systemic lupus erythematosus and other autoimmune diseases","volume":"25","author":"Banchereau","year":"2006","journal-title":"Immunity"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib1320","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1038\/ncomms4016","article-title":"High efficiency cell-specific targeting of cytokine activity","volume":"5","author":"Garcin","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib1325","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1084\/jem.20101664","article-title":"Type I interferon: friend or foe?","volume":"207","author":"Trinchieri","year":"2010","journal-title":"J Exp Med"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib1330","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/COH.0b013e3283499cf6","article-title":"Generalized immune activation and innate immune responses in simian immunodeficiency virus infection","volume":"6","author":"Bosinger","year":"2011","journal-title":"Curr Opin HIV AIDS"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib1335","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/rmv.1708","article-title":"Innate immune interferon responses to human immunodeficiency virus-1 infection","volume":"22","author":"Hughes","year":"2012","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib1340","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1126\/science.1235214","article-title":"Persistent LCMV infection is controlled by blockade of type I interferon signaling","volume":"340","author":"Teijaro","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib1345","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1126\/science.1235208","article-title":"Blockade of chronic type I interferon signaling to control persistent LCMV infection","volume":"340","author":"Wilson","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib1350","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/nature13554","article-title":"Type I interferon responses in rhesus macaques prevent SIV infection and slow disease progression","volume":"511","author":"Sandler","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib1355","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1056\/NEJM198401053100104","article-title":"Alpha interferon for induction of remission in hairy-cell leukemia","volume":"310","author":"Quesada","year":"1984","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib1360","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1182\/blood.V69.5.1280.1280","article-title":"Clinical investigation of human alpha interferon in chronic myelogenous leukemia","volume":"69","author":"Talpaz","year":"1987","journal-title":"Blood"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib1365","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/JCO.1996.14.1.7","article-title":"Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684","volume":"14","author":"Kirkwood","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib1370","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMoa003013","article-title":"Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer","volume":"345","author":"Flanigan","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib1375","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1126\/science.146.3650.1472","article-title":"Interferon-like viral inhibitor in rabbits after intravenous administration of endotoxin","volume":"146","author":"Ho","year":"1964","journal-title":"Science"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib1380","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1073\/pnas.58.3.1004","article-title":"Inducers of interferon and host resistance. II. Multistranded synthetic polynucleotide complexes","volume":"58","author":"Field","year":"1967","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib1385","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/250057a0","article-title":"Increased sensitivity of cell-free protein synthesis to double-stranded RNA after interferon treatment","volume":"250","author":"Kerr","year":"1974","journal-title":"Nature"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib1390","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/41131","article-title":"A human homologue of the Drosophila Toll protein signals activation of adaptive immunity","volume":"388","author":"Medzhitov","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib1395","doi-asserted-by":"crossref","first-page":"15623","DOI":"10.1073\/pnas.95.26.15623","article-title":"Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays","volume":"95","author":"Der","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib1400","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/35099560","article-title":"Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3","volume":"413","author":"Alexopoulou","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib1405","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/ni875","article-title":"IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex","volume":"4","author":"Kotenko","year":"2003","journal-title":"Nat Immunol"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib1410","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/ni873","article-title":"IL-28, IL-29 and their class II cytokine receptor IL-28R","volume":"4","author":"Sheppard","year":"2003","journal-title":"Nat Immunol"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib1415","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/ni1087","article-title":"The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses","volume":"5","author":"Yoneyama","year":"2004","journal-title":"Nat Immunol"},{"key":"10.1016\/j.cytogfr.2014.12.006_bib1420","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1038\/nature06205","article-title":"Interferon modulation of cellular microRNAs as an antiviral mechanism","volume":"449","author":"Pedersen","year":"2007","journal-title":"Nature"}],"container-title":["Cytokine &amp; Growth Factor Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359610114001701?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359610114001701?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,7,31]],"date-time":"2023-07-31T06:21:19Z","timestamp":1690784479000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359610114001701"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":142,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["S1359610114001701"],"URL":"https:\/\/doi.org\/10.1016\/j.cytogfr.2014.12.006","relation":{},"ISSN":["1359-6101"],"issn-type":[{"value":"1359-6101","type":"print"}],"subject":[],"published":{"date-parts":[[2015,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Twenty-five years of type I interferon-based treatment: A critical analysis of its therapeutic use","name":"articletitle","label":"Article Title"},{"value":"Cytokine & Growth Factor Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cytogfr.2014.12.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}